Acute Heart Failure (AHF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Acute Heart Failure (AHF) Market Outlook

Thelansis’s “Acute Heart Failure (AHF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Heart Failure (AHF) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Acute Heart Failure (AHF) Overview

Acute heart failure (AHF) is the sudden onset or worsening of symptoms and signs associated with heart failure (HF). This critical condition typically requires hospitalization, focusing on the immediate management of fluid overload and compromised hemodynamics. It encompasses individuals experiencing typical HF symptoms and signs for the first time (de novo AHF) and those with exacerbated symptoms of their existing cardiomyopathy (acute decompensated heart failure). Heart failure (HF) is a clinical syndrome characterized by symptoms, including breathlessness, difficulty breathing while lying down, lower limb swelling, and signs such as elevated jugular vein pressure and lung congestion. These manifestations result from structural and functional abnormalities in the heart, leading to reduced cardiac output and increased pressures within the heart. More than 50% of patients in high-income regions and Eastern and Central European areas, acute heart failure admissions are primarily linked to ischemic heart disease. Globally, hypertension consistently contributes to the occurrence of heart failure. The most common HF symptoms include exertional or resting breathlessness, discomfort when lying flat (orthopnea), fatigue, and reduced exercise capacity. These symptoms are often accompanied by clinical signs such as limb swelling, distended jugular veins, a third heart sound called the “S3 gallop,” and pulmonary rales. The European Society of Cardiology (ESC) classified heart failure patients into six groups based on their clinical presentations:

1. Acute decompensated congestive heart failure involves worsening chronic heart failure, characterized by a gradual onset of peripheral edema and significant dyspnea.
2. AHF with hypertension: This is marked by a rapid increase in systolic blood pressure, pulmonary congestion, tachycardia, preserved left ventricular ejection fraction (LVEF), and relatively low mortality.
3. AHF with pulmonary edema: This presents with sudden or gradual severe respiratory distress, widespread lung rales, tachypnea, orthopnea, and arterial oxygen saturation (SaO2) below 90%.
4. Cardiogenic shock: This is a highly fatal syndrome characterized by gradual or rapid organ and tissue hypoperfusion, reduced urine output, and systolic blood pressure below 90 mm Hg.
5. AHF complicating acute coronary syndrome (ACS): This results from increased left ventricular diastolic filling pressure or decreased cardiac output due to myocardial ischemia or infarction.
6. Isolated right-sided AHF: This is characterized by rapid or gradual edema onset, jugular vein distention, hepatomegaly, clear lungs, low blood pressure, reduced left ventricular filling pressure, and decreased cardiac output.

The first-line treatment for acute heart failure is loop diuretics. These drugs include furosemide, bumetanide, and torsemide.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Acute Heart Failure (AHF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034